Iraq
Tuberculosis profile
Population  2012 33 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.96 (0.025–3.5) 2.9 (0.08–11)
Mortality (HIV+TB only) 0 (0–0) 0 (0–0)
Prevalence  (includes HIV+TB) 24 (12–40) 73 (36–122)
Incidence  (includes HIV+TB) 15 (13–17) 45 (39–51)
Incidence (HIV+TB only) 0 (0–0) 0 (0–0)
Case detection, all forms (%) 59 (52–68)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 2 760 (33) Relapse 328 (43)
Smear-negative 1 860 (22) Treatment after failure 79 (10)
Smear-unknown / not done 455 (5) Treatment after default 39 (5)
Extrapulmonary 3 261 (39) Other 317 (42)
Other 0 (0)      
Total new 8 336   Total retreatment 763  
           
Other (history unknown) 0        
Total new and relapse 8 664   Total cases notified 9 099  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.1 1.0 0.7
Age < 15 63 211 373
Laboratories 2012
Smear (per 100 000 population) 0.8
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 0.2
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 89   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 90  
Retreatment 75  
TB/HIV 2012 Number (%)
TB patients with known HIV status 7 821 (86)
HIV-positive TB patients 2 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 1 (50)
HIV-positive TB patients on antiretroviral therapy (ART) 1 (50)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 3.5 (0.1–12) 32 (7.5–56)
MDR-TB cases among notified pulmonary
TB cases
180 (5–610) 240 (57–430)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 69 (3%) 159 (21%) 228
Laboratory-confirmed MDR-TB cases 3 59 62
Patients started on MDR-TB treatment     66
Financing TB control 2013
National TB programme budget (US$ millions) 27
% Funded domestically 83%
% Funded internationally 13%
% Unfunded 4%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-23 Data: www.who.int/tb/data